J.S.P. Property Public Company Limited

JSP has unveiled its plan to expand into international markets in the second half of 2026, using the Suphap Osot brand to penetrate the Chinese market through live commerce channels, amid slowing domestic purchasing power and intense online competition. The company is preparing to expand its presence in China through label agents and leverage content from Thailand to build on its momentum. Meanwhile, it is also eyeing opportunities in Vietnam, Malaysia, Indonesia, and the Middle East, while expanding into the functional FMCG market with its black coffee product, which has been well received. For the second quarter of 2026, the company reported revenue of 236.60 million baht and net profit of 10.03 million baht, while for the first six months, revenue stood at 437.89 million baht and net profit at 10.87 million baht.

Mr. Phitsanu Daengprasert, chairman of JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited, revealed that based on sales data collected from 185 automated medicine vending machines in Bangkok and its vicinity over the past year, sexual health products accounted for the highest sales share at 29%, particularly in university areas. The top-selling product category was condoms, with sales of 1.61 million baht, followed by hangover jelly at 636,333 baht, lubricant gel at 609,375 baht, and 4-in-1 test kits at 480,965 baht. Other categories included general household medicines at 16.2%, candies and lozenges at 12.8%, personal care and hygiene items at 12.6%, and health test kits at 11.0%. JSP believes that purchasing through vending machines appeals to the younger generation due to privacy and easy access, and notes that this behavior is a positive sign for sexual health prevention amid the HIV situation, with an average of 8,000-9,000 new infections per year, syphilis cases rising 2.7 times to 11,813, and gonorrhea cases increasing 2.5 times to 9,897. The company is ready to support the expansion of "Warm Heart Medicine Vending Machine" service points and continue its strategy to grow its health business, including pharmaceuticals, supplements, and health products, through retail stores, online channels, and vending machines.

JSP is confident that revenue in 2026 will grow as targeted, despite first-half profit being pressured by volatile oil and packaging costs. Group CEO Dr. Sittichai Daengprasert revealed that the company is driving its business through three core strategies: the OEM business, which continues to grow thanks to rising demand for health products; the company's own brand under the name Supap Osot, which is seeing clear growth especially through online channels; and mergers and acquisitions to strengthen capabilities, with existing subsidiaries continuing to grow and additional opportunities under consideration.